Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects With Moderate to Severe Ulcerative Colitis (LOMBARD)

NCT04583358 is registered in ClinicalTrials.gov with Applied Molecular Transport as lead sponsor.

NCT NCT04583358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04583358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects With Moderate to Severe Ulcerative Colitis (LOMBARD)
Lead sponsor
Applied Molecular Transport
Phase
Phase 2
Overall status
Unknown status
Start date
August 26, 2020
Completion date
December 31, 2022
Enrollment
105 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis